Skip to main content

Table 1 Demographic and baseline clinical characteristics of study participants

From: Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy

Subject ID

Group

Ethnicity

Gender

Birth Mode

Gestational Term

a Antibiotics intake prior to diagnosis

b Risk Group

Chemotherapy duration (months)

Follow-up Duration (months)

AL3

Patient

Malay

Female

Vaginal

Term

Yes

Intermediate

27

34

AL4

Patient

Malay

Male

NA

Term

Yes

Standard

25

34

AL8

Patient

Malay

Male

Vaginal

Term

Yes

Standard

25

29

AL10

Patient

Malay

Male

Vaginal

Term

Yes

Intermediate

27

31

AL13

Patient

Malay

Male

Vaginal

Term

Yes

Standard

25

30

AL15

Patient

Malay

Male

Vaginal

Term

Yes

Intermediate

26

31

AL18

Patient

Malay

Male

Vaginal

Post-term

Yes

Standard

24

29

      

a Antibiotics intake prior to sampling

   

IM18C

Control

Malay

Male

Vaginal

Term

No

ConC1

Control

Malay

Male

Vaginal

Term

No

ConC2

Control

Malay

Male

Vaginal

Term

No

ConC4

Control

Malay

Female

Vaginal

Term

No

ConC5

Control

Malay

Male

Vaginal

Term

No

ConCP3

Control

Malay

Male

Vaginal

Term

No

ConCP5

Control

Malay

Male

Vaginal

Term

No

  1. NA no information available
  2. aAntibiotic intake within 1 month prior to baseline sample collection
  3. bRisk group = ALL patients were assigned to one of the 3 risk groups (ie: standard, intermediate, high), depending on their response to the chemotherapy and special laboratory tests, according to Ma-Spore ALL 2010 treatment protocol